Aknar Calabrich

Aknar Calabrich

Auto-generated profile, based on publicly available information

Aknar Calabrich

Clínica AMO - Department of Clinical Oncology , Salvador

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
CSCinthya Sternberg
Cinthya Sternberg
TAThamine Lessa Andrade
Thamine Lessa Andrade
ANAna Paula Gomes Alcântara Villa Nova
Ana Paula Gomes Alcântara Villa Nova
BFBianca Vivas Fiscina
Bianca Vivas Fiscina
AFAna Paula Laranjeira Fernandes
Ana Paula Laranjeira Fernandes
ASAlex Pimenta da Silva
Alex Pimenta da Silva
SUMMARY The first confirmed case of coronavirus disease 2019 (COVID-19) in Brasil was reported on February 25th, 2020, and by April 3rd, 8076 were confirmed in the country. As COVID-19 disease incidence escalates in Brasil, management of cancer patients requires immediate action and oncology clinics are urged to establish a contingency plan. We have installed a COVID-19 Management Committee to elaborate and implement best practices to assist cancer outpatients as well as to provide a safe environment for clinical staff and other employees at the outpatient clinics. The challenges of cancer treatment in the midst of COVID-19 global pandemic highlight the importance of a rapid response by institutions, where organizational structure, strategic planning, agility in guidelines implementation and alternative ways to protect and support clinical staff, employees and patients may be the key to mitigate pandemic effects.

22 July 2024 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
RRReitan Ribeiro
Reitan Ribeiro
FCFilomena Marino Carvalho
Filomena Marino Carvalho
GBGlauco Baiocchi
Glauco Baiocchi
RGRodrigo Santa Cruz Guindalini
Rodrigo Santa Cruz Guindalini
JCJuliano Rodrigues da Cunha
Juliano Rodrigues da Cunha
HRHeber Salvador de Castro Ribeiro
Heber Salvador de Castro Ribeiro

1 September 2023 in JCO Global Oncology
Verified
Journal Article
Open access
TMTatiane Montella
Tatiane Montella
MZMariano Zalis
Mariano Zalis
MZMauro Zukin
Mauro Zukin
VLVLADMIR Cláudio CORDEIRO DE LIMA
VLADMIR Cláudio CORDEIRO DE LIMA
CBClarissa Baldotto
Clarissa Baldotto
CFCarlos Gil Ferreira
Carlos Gil Ferreira
PURPOSE: There is a paucity of consistent data concerning genetic mutations in Brazilian patients with lung cancer. The aim of this study was to retrospectively analyze epidermal growth factor receptor (EGFR) mutations detected in a real-world scenario using a large cohort of Brazilian patients with non–small-cell lung cancer (NSCLC). MATERIALS AND METHODS: This was a cross-sectional, observational, descriptive study on the basis of a database of EGFR molecular analysis from tumor samples of patients with a confirmatory histopathological diagnosis of primary lung cancer. Specimens were collected from 2013 to 2017 and were tested using cobas, next-generation sequencing, and Sanger sequencing platforms. RESULTS: A total of 7,413 tumor specimens were tested. The patients were predominantly women with a median age of 67.0 years. Patients with at least one mutation represented 24.2% of the total sample. Among the positive patients, the majority had just one mutation, but two or more simultaneous mutations were observed in 1.52% of patients. Exon 19 deletion was the most prevalent alteration in the sample (12.8%), followed by exon 21 L858R (6.9%) and exon 20 insertion (1.6%). All others were considered uncommon mutations and were observed in 18.5% of all mutated patients and 4.0% of the total sample (2.3%-18.7% depending on the sequencing method). CONCLUSION: This study examined the prevalence of EGFR mutations in Brazilian patients with NSCLC using different technologies, suggesting that the type of method used, directed or nondirected against specific mutations, influences the analysis, particularly for uncommon mutations, which will be missed by mutation-specific approaches such as cobas testing. Our estimates are the largest in Latin America and are consistent with previous reports from other parts of the world. Besides the variability in methods described here as technology incorporation advances in a nonhomogeneous manner, it is probably like the real-world clinical setting Brazilian oncologists face in their daily practice.

24 July 2026 in Neuro-Oncology Practice
Verified
Journal Article
Closed access
CYCamilla Akemi Felizardo Yamada
Camilla Akemi Felizardo Yamada
MMMarcos Vinicius Calfat Maldaun
Marcos Vinicius Calfat Maldaun
FVFabiana Spilari Viola
Fabiana Spilari Viola
CBClarissa Baldotto
Clarissa Baldotto
FMFernando C Maluf
Fernando C Maluf
SMSuzana Maria Fleury Malheiros
Suzana Maria Fleury Malheiros
Background: Diffuse gliomas in adults are rare, aggressive central nervous system (CNS) tumors whose outcomes are strongly influenced by molecular features. In Brazil, data on epidemiology, molecular diagnostics, and survival are scarce, particularly following the WHO CNS 2021 classification. The LACOG 0619 RWD (Real-World Data) addresses this gap by characterizing Brazilian diffuse glioma patients and evaluating diagnostic disparities. Methods: This retrospective, multicenter cohort included adults (≥18 years) with histologically confirmed diffuse gliomas from 9 centers in Brazil (2010-2019). Reclassification followed WHO CNS 2021 criteria. Completeness of molecular workup was compared between public and private institutions. Results: A total of 828 patients were included (median age 52 years, 56.0% male, 57.6% from private centers). Glioblastoma was the most frequent histology (57%). The central finding was a marked disparity in access to molecular diagnostics: IDH (Isocitrate Dehydrogenase), 1p/19q, MGMT (O6-Methylguanine-DNA Methyltransferase), and Next-Generation Sequencing testing were far more frequent in private institutions. Although testing rates improved after 2016, <20% of eligible cases underwent IDH sequencing. Survival differed by histology and WHO 2021 criteria, with 5-year overall survival ranging from 20.2% in IDH-wildtype glioblastoma to 90.9% in IDH-mutant grade 2 gliomas (P < .001), confirming the prognostic impact of molecular testing. Conclusions: LACOG 0619 is the first and largest RWD to assess molecular diagnostic gaps in diffuse gliomas in Brazil. The study reveals profound inequities between public and private healthcare institutions, underscoring the urgent need to expand equitable access to molecular testing as an essential step toward enhancing patient care and ensuring inclusion in precision oncology.

1 June 2010 in Clinics
Verified
Journal Article
Open access
PDF file
GFGustavo dos Santos Fernandes
Gustavo dos Santos Fernandes
AKAtur Katz
Atur Katz
ACAknar Calabrich
Aknar Calabrich
PHPaulo M. Hoff
Paulo M. Hoff

1 June 2026 in JCO Global Oncology
Verified
Journal Article
Closed access
EMEldsamira Mascarenhas
Eldsamira Mascarenhas
AGAna C. Z. Gelatti
Ana C. Z. Gelatti
TMTatiane Montella
Tatiane Montella
MCMarcelo Corassa
Marcelo Corassa
WWWilliam William
William William
CFCarlos Gil Ferreira
Carlos Gil Ferreira
PURPOSE: ALK rearrangements occur in 5.4% of Brazilian patients with non–small cell lung cancer (NSCLC). Data on treatment patterns, access to ALK inhibitors, and survival outcomes are scarce. MATERIALS AND METHODS: LACOG/GBOT 1918 is a retrospective, observational study that included patients diagnosed with ALK-positive NSCLC between January 2015 and December 2020 in 12 Brazilian public and private centers. Data were extracted from patient records, including clinic-epidemiologic features, diagnosis, ALK testing methods, treatment patterns, and outcomes. Data were analyzed using descriptive statistical methods. RESULTS: A total of 101 patients were enrolled. The median age was 55 years (range, 18-86), and 55.4% were female. Immunohistochemistry was the most frequently used method for ALK testing. The median time from the first symptom to diagnosis was 2 months, from diagnosis to ALK testing 1.7 months, and from diagnosis to treatment initiation 1.7 months. Among patients receiving first-line treatment, only 47.9% received ALK inhibitors (53.9% private v 22.2% public), with crizotinib being the most used. For second-line treatment, 66.0% of patients received ALK inhibitors, with alectinib being the most used (50%). Most treated patients had access to ALK inhibitors in some line of treatment (83.3% private v 72.2% public); however, in the public setting, targeted treatment was restricted to first-generation and second-generation ALK inhibitors. The 3-year overall survival (OS) rate was 82.6% (95% CI, 72.6 to 89.2), with a lower 3-year OS in the public setting (61.4% public v 87.2% private; P = .0279). CONCLUSION: Access to targeted ALK therapy is limited in the public health care system, reflecting poor clinical outcomes. Public health measures are necessary to minimize the differences between these two systems.